Phase 3 N=343 A Study For Pregabalin In Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14 — -2.01; -1.28 Units on a scale — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,146 Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Irritable Bowel Syndrome
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores — 28.9…
Phase 3 N=3,005 Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Migraine With or Without Aura
Primary: Percentage of Participants Headache Pain Free at 2 Hours Post Dose — 28.6; 31.4; 38.8; 21.3 percentage of participants — p=0.003
Phase 3 N=13 A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
Autosomal Dominant Polycystic Kidney Disease
Primary: Total Kidney Volume — 1428; 1675; 1728; 1775 mL
Phase 3 N=171 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Epilepsy · Lennox-Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -43.90; -21.80 percentage change — p=0.0135
Phase 3 N=795 Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) — 0.8; 3.8; 2.3; 4.4 percent change — p=< 0.001
Phase 3 N=225 Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Epilepsy · Lennox Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -41.86; -37.16; -17.17 percentage change — p=0.0047
Phase 3 N=52 Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
Seizures
Primary: Percentage of Participants With Adverse Events — 88.9; 92.3; 88.2; 90.4 Percentage of participants
Phase 3 N=407 Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy
Atrial Fibrillation · Stroke
Primary: Primary Safety Endpoint (Device Group Only) — 6 Participants
Phase 3 N=194 Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
Cognitive/Functional Effects · Metastatic Cancer · Neurotoxicity
Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001
Phase 3 N=268 DFN-11 Injection in Episodic Migraine With or Without Aura
Episodic Migraine
Primary: The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary — 51.0; 30.8 Percentage of…
Phase 3 N=506 Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Parkinson's Disease · Dyskinesia
Primary: Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at Week 12 — 30.4; 33.2 percentage of subjects
Phase 3 N=752 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Incidence of Adverse Events (AEs) — 98.5; 42.6; 68.9; 23.8 Percentage of patients (%)
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
Phase 3 N=168 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
High Risk Polycythemia Vera · High Risk Essential Thrombocythemia
Primary: Number of Participants With Complete Remission (CR) — 17; 19; 12; 13 Participants